SCHEMBL224110

SCHEMBL224110

O=Cc1cc(F)cc(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.42
ERN1 O75460 4/20 0.39
ALDH1A1 P00352 1/20 0.38
EPAS1 Q99814 3/20 0.34
AHR P35869 1/20 0.33
PGR P06401 1/20 0.33
RAPGEF4 Q8WZA2 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29937848 1.00 HSD17B10 (0.42) HSD17B10ERN1ALDH1A1EPAS1AHR
SCHEMBL18002847 0.87 AHR (0.42) HSD17B10ERN1AHR
SCHEMBL96269 0.82 ERN1 (0.41) ERN1ALDH1A1
SCHEMBL6854243 0.82 ERN1 (0.41) ERN1ALDH1A1
SCHEMBL3477069 0.82 HSD17B10 (0.52) HSD17B10ERN1ALDH1A1AHRTDP1
SCHEMBL42392 0.82 HSD17B10 (0.52) HSD17B10ERN1ALDH1A1AHRTDP1
Hydrochloric Acid SCHEMBL28632193 0.79 HSD17B10 (0.50) HSD17B10ERN1ALDH1A1AHRTDP1
Ammonia Solution, Strong SCHEMBL13735346 0.79 ERN1 (0.39) ERN1ALDH1A1
SCHEMBL21631073 0.79 ALDH1A1 (0.39) ALDH1A1AHR
SCHEMBL27286024 0.77 TSHR (0.44) ERN1EPAS1AHRPGRRAPGEF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118496215-A Polyhydroxylated onium derivative with disubstituted benzene ring, preparation method and medical application thereof 中国药科大学 2024-08-16 CN claimed
CN-117624148-A Polyhydroxy sulfonium salt derivative with disubstituted benzene ring, preparation method and medical application thereof 中国药科大学 2024-03-01 CN claimed
US-RE48335-E1 Polymyxin derivatives as antimicrobial compounds MONASH UNIVERSITY (AU) 2020-12-01 US claimed
CN-106414480-B Polymyxin derivatives as antimicrobial compounds 莫纳什大学 2020-08-04 CN claimed
US-20170137469-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS MONASH UNIVERSITY (AU) 2017-05-18 US claimed
EP-3126376-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS Monash University (AU) 2017-02-08 EP claimed
WO-2015149131-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS MONASH UNIVERSITY (AU) 2015-10-08 WO claimed
US-20260042758-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV DISCOVERY (FR) 2026-02-12 US disclosed
US-12545685-B2 Dispiropyrrolidine derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2026-02-10 US disclosed
EP-4430037-B1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORP (US) 2025-10-29 EP disclosed
EP-4626891-A1 FUSED PYRIMIDINES AS MASP-2 INHIBITORS Omeros Corporation (US) 2025-10-08 EP disclosed
EP-4447962-B1 ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER UNIV GENEVE (CH) 2025-08-20 EP disclosed
WO-2025104443-A1 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2025-05-22 WO disclosed
WO-2006034093-A2 3- (2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS ELLI LILLY AND COMPANY (US) 2006-03-30 WO disclosed
CN-1649865-A Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists NPS PHARMA INC (US) 2005-08-03 CN disclosed
EP-0318704-B1 3-CYANO-4-PHENYL-PYRROLE DERIVATIVES BAYER AG (DE) 1992-12-02 EP disclosed
EP-0339417-B1 3-CYANO-4-PHENYL-PYRROLES BAYER AG (DE) 1991-09-11 EP disclosed
US-5015757-A Fungicides BAYER AKTIENGESELLSCHAFT (DE) 1991-05-14 US disclosed
US-4960789-A FUNGICIDES BAYER AKTIENGESELLSCHAFT (DE) 1990-10-02 US disclosed
EP-0318704-A2 3-Cyano-4-phenyl-pyrrole derivatives BAYER AG (DE) 1989-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545685-B2 Dispiropyrrolidine derivatives TP53, MDM2, TP53BP1 HSD17B10 2895/4885ERN1 1336/4885ALDH1A1 2383/4885
US-20260042758-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS BRAF, RAF1, NRAS HSD17B10 3563/4885ERN1 489/4885ALDH1A1 1307/4885
US-20170137469-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS VIP, PEPD, NRDC HSD17B10 4287/4885ERN1 1340/4885ALDH1A1 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.